期刊文献+

Lp-PLA2酶法测定试剂盒的临床应用评价

The Evaluation of Clinical Application of the Lp-PLA2 DiagnosticKit-Enzyme Activity Determination
下载PDF
导出
摘要 目的验证北京九强金斯尔脂蛋白相关磷脂酶A2(Lp-PLA2)酶法测定试剂盒的性能指标,评价其是否符合临床需求。方法根据WS/T492-2016《临床检测定量测定项目精密度与正确度性能验证》、CNAS-GL037:2019《临床化学定量检验程序性能验证指南》及WST402-2012《临床实验室检验项目参考区间的制定》等文件要求,对北京九强金斯尔Lp-PLA2酶法测定试剂盒的正确度、精密度、线性范围、可报告范围和生物参考区间等性能进行验证,并与上海润鸿Lp-PLA2测定试剂盒进行方法学比对。结果正确度验证中,金斯尔Lp-PLA2酶法测定试剂盒测定厂家工作标准品偏差均小于8%;检测配套高低两水平质控品,每个水平检测的重复性和实验室内精密度的变异系数(CV)均在±2%范围内;在线性区间评价试验中,得到线性回归方程Y=1.0054 X-3.3466,R 2=0.9998。验证线性区间为58.53~1181.07U/L,最大可稀释倍数为64倍,临床可报告上限水平为75588.48U/L。厂家提供的生物参考区间男性:230~728U/L,女性:194~640U/L(18~49岁)和208~698U/L(50~88岁)均通过验证,可适用于临床。此外,与上海润鸿Lp-PLA2测定试剂盒进行方法学比对,其相关性回归分析结果为,Y=1.259 X-23.558,R 2=0.9989。结论北京九强金斯尔Lp-PLA2测定试剂盒的各性能指标均可达到行业标准及厂家声明的要求,与上海润鸿试剂盒检测结果一致性较好,可满足临床需求。 Objective To verify the performance of the enzymatic assay kit for lipoprotein-associated phospholipase A2(Lp-PLA2)of Beijing Jiuqiang Gcell,and to evaluate whether it meets the clinical requirements.Methods According to multiple guidelines,including WS/T492-2016 document(Verification of performance for precision and trueness of quantitative measurements in clinical laboratories),CNAS-GL037:2019(Guidance on the verification of quantitative measurement procedures used in the clinical chemistry)and the profile of WS/T402-2012(Define and determine the reference intervals in clinical laboratory),the performance of Beijing Jiuqiang Gcell Lp-PLA2 enzymatic assay kit for its accuracy,precision,linear range,reportable range and biological reference interval were verified.The performance of this methodology was compared with that of Shanghai Runhong Lp-PLA2 assay kit.Results In the verification of accuracy,the deviation of Gcell Lp-PLA2 enzymatic assay kit in determining the working standards of manufacturers was less than 8%.Two levels of quality control products were tested,and the repeatability of each level and the coefficient of variation(CV)of laboratory precision were within 2%.In the linear interval evaluation test,the linear regression equation was:Y=1.0054 X-3.3466,R 2=0.9998.The linear range was 58.53-1181.07U/L,the maximum dilution factor was 64 times,and the upper limit of clinical reportable level was 75588.48U/L.The biological reference intervals provided by the manufacturer was following:male:230-728U/L,female:194-640U/L(18-49 years old)and 208-698 U/L(50-88 years old).Our results had passed the verification and could be applied to clinic use.In addition,compared with Shanghai Runhong Lp-PLA2 assay kit,the results of correlation regression analysis were:Y=1.259 X-23.558,R 2=0.9989.Conclusion All the performance indexes of Beijing Jiuqiang Gcell Lp-PLA2 assay kit can meet the requirements of industry standards and manufacturers’statements,and the results are in a good agreement with those of Shanghai Runhong assay kit,which can meet the clinical needs.
作者 孙龙乔子 黄利思 丘元福 胡慧灵 张小凡 何川疆 卢晓霞 段朝晖 SUN Longqiaozi;HUANG Lisi;QIU Yuanfu;HU Huiling;ZHANG Xiaofan;HE Chuanjiang;LU Xiaoxia;DUAN Chaohui(Department of Clinical Laboratory,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510275,China)
出处 《标记免疫分析与临床》 CAS 2023年第5期846-850,共5页 Labeled Immunoassays and Clinical Medicine
基金 国家重点研发计划项目(编号:2021YFC2009300,2021YFC2009302)。
关键词 脂蛋白相关磷脂酶A2 酶活性法 AU5800 性能验证 方法学比对 Lipoprotein-associated phospholipase A2 Enzyme activity method AU5800 Performance verification Methodological comparison
  • 相关文献

参考文献7

二级参考文献43

  • 1Maiolino G, Pedon L, Cesari M, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PloS One, 2012, 7: e48171.
  • 2Hassan M. STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Glob Carrtiol Sci Pracl, 2015, 2015: 6.
  • 3Burke J, Dennis E. Phospholipase A2 biochemistly. Cardiovasc Drugs Ther, 2009, 23: 49-59.
  • 4Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL. Curr Pharm Des, 2014, 20: 6256-6269.
  • 5Xu RX, Zhang Y, Li XL, et al. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Clin Cbim Aeta, 2015, 446: 195-200.
  • 6Yang M, Chu EM, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes. Biochim Biophys Acta, 2010, 1801: 176-182.
  • 7Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis, 2011, 10: 170.
  • 8Kolodgie F, Burke A, Skorija K, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atheroselerosis. Arterioscler Thromh Vasc Biol, 2006, 26: 2523-2529.
  • 9Fenning RS, Burgert ME, Hamamdzic D, et al. Atherosclerotic plaque inflammation varies between vascular sites and correlates with respons to inhibition of lipoprotein-associated phospholipase A2. J Am Heart Assoc, 2015, 4. pii: e001477, doi: 10. ll61/JAHA. 114. 001477.
  • 10Thompson A, Gao P, Orfei L, et al. Lip0protein-assoeiated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospeetive studies. Laneet, 2010, 375: 1536-1544.

共引文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部